ARTICLE | Company News

Hisamitsu, Shire sales and marketing update

August 23, 2010 7:00 AM UTC

Hisamitsu's Noven Pharmaceuticals Inc. subsidiary will reacquire ADHD drug Daytrana methylphenidate transdermal system (formerly MethylPatch) from Shire. Shire said it will receive consideration from Noven based on a percentage of Noven's future sales, which will be accounted for as deferred consideration. Specific details were not disclosed.

Shire attributed the decision in part to a usability issue associated with removing the release liner. It also said its market share for Daytrana in the ADHD market was less than 1%. The transdermal methylphenidate patch had 1H09 sales of $34.7 million. The deal is expected to close on Oct. 1. ...